First Experience and Clinical Results Using a New Non-coplanar Mono-isocenter Technique (HyperArc™) for Linac-based VMAT Radiosurgery in Brain Metastases

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2018 Nov 2

PMID 30382369

Citations 43

Authors

Filippo Alongi

Alba Fiorentino

Fabiana Gregucci

Stefanie Corradini

Niccolo Giaj-Levra

Luigi Romano

Michele Rigo

Francesco Ricchetti

Alberto Beltramello

Gianluigi Lunardi

Rosario Mazzola

Ruggero Ruggieri

Affiliations

Soon will be listed here.

Abstract

Introduction: Radiosurgery (SRS) or stereotactic fractionated radiotherapy (SFRT) is increasing in the treatment of brain metastases (BMs). Aim of the present study was to evaluate the safety and effectiveness of SRS/SFRT for BMs, using a new mono-isocenter non-coplanar solution (HyperArc™ Varian Medical System).

Methods: BMs patients with a diameter inferior to 3 cm, a life expectancy of more than 3 months and a good performance status, were eligible for Linac-based volumetric modulated arc therapy (VMAT) SFRT/SRS with HyperArc™. A retrospective analysis of patients and BMs was performed.

Results: From August 2017 to May 2018, 381 BMs in 64 patients were treated and 246 BMs (43 patients, median number of BMs: 5) of them were suitable for analysis. With a median FU time of 6 months, 244 out 246 (99%) BMs were controlled (18% complete response; 41% partial response, 40% stable disease), 2 BMs showed a progression, at the first control. No acute or late toxicities were reported. Median overall survival (OS) has not yet been achieved, while median time to progression was 5 months. In univariate analysis, statistically negative prognostic factors for OS were histology of primary tumor (p = 0.009): lung/breast cancer had better survival rates as compared to others. Cumulative intracranial volume disease ≥ 15 cc and systemic progression disease were independent prognostic factors for OS at univariate (p = 0.04; p = 0.005) and multivariate (p = 0.04; p = 0.009) analysis, respectively.

Conclusion: The present first clinical data show that SFRT/SRS with HyperArc™ is safe and effective for BMs patients. The utilization of SFRT/SRS for BMs is promising and should be further explored in randomized trials.

Citing Articles

A Dosimetric Comparison of HyperArc Therapy Planning and Volumetric Modulated Arc Therapy Planning in Treating Patients With Glioblastoma Multiforme.

Hong W, Ho H, Lin H, Lin T, Chow W, Yang C In Vivo. 2025; 39(2):1009-1021.

PMID: 40011001 PMC: 11884473. DOI: 10.21873/invivo.13906.

Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report.

Surgo A, Davi V, Ciliberti M, Carbonara R, Caliandro M, Di Guglielmo F Curr Oncol. 2024; 31(12):8118-8126.

PMID: 39727721 PMC: 11675016. DOI: 10.3390/curroncol31120598.

Optimization of sub-arc collimator angles in volumetric modulated arc therapy: a heatmap-based blocking index approach for multiple brain metastases.

Huang S, Yang S, Zeng B, Li X Phys Eng Sci Med. 2024; 47(4):1639-1650.

PMID: 39235667 DOI: 10.1007/s13246-024-01477-y.

Dosimetric comparison of ZAP-X, Gamma Knife, and CyberKnife stereotactic radiosurgery for single brain metastasis.

Wang J, Zheng Q, Wang Y, Wang C, Xu S, Ju Z BMC Cancer. 2024; 24(1):936.

PMID: 39090564 PMC: 11295608. DOI: 10.1186/s12885-024-12710-y.

Biological Insights and Radiation-Immuno-Oncology Developments in Primary and Secondary Brain Tumors.

Gregucci F, Beal K, Knisely J, Pagnini P, Fiorentino A, Bonzano E Cancers (Basel). 2024; 16(11).

PMID: 38893165 PMC: 11171192. DOI: 10.3390/cancers16112047.

References

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R . Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008; 155(2):185-97. PMC: 2538693. DOI: 10.1038/bjp.2008.260. View

Lin N, Claus E, Sohl J, Razzak A, Arnaout A, Winer E . Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113(10):2638-45. PMC: 2835546. DOI: 10.1002/cncr.23930. View

Muller-Riemenschneider F, Bockelbrink A, Ernst I, Schwarzbach C, Vauth C, von der Schulenburg J . Stereotactic radiosurgery for the treatment of brain metastases. Radiother Oncol. 2009; 91(1):67-74. DOI: 10.1016/j.radonc.2008.12.001. View

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

Kennecke H, Yerushalmi R, Woods R, Chon U Cheang M, Voduc D, Speers C . Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28(20):3271-7. DOI: 10.1200/JCO.2009.25.9820. View

Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert B . Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2010; 29(2):134-41. PMC: 3058272. DOI: 10.1200/JCO.2010.30.1655. View

Wiggenraad R, Verbeek-de Kanter A, Kal H, Taphoorn M, Vissers T, Struikmans H . Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol. 2011; 98(3):292-7. DOI: 10.1016/j.radonc.2011.01.011. View

Minniti G, Clarke E, Lanzetta G, Osti M, Trasimeni G, Bozzao A . Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011; 6:48. PMC: 3108308. DOI: 10.1186/1748-717X-6-48. View

10.

Scoccianti S, Ricardi U . Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol. 2011; 102(2):168-79. DOI: 10.1016/j.radonc.2011.08.041. View

11.

Nayak L, Quant Lee E, Wen P . Epidemiology of brain metastases. Curr Oncol Rep. 2011; 14(1):48-54. DOI: 10.1007/s11912-011-0203-y. View

12.

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

13.

Margolin K, Ernstoff M, Hamid O, Lawrence D, McDermott D, Puzanov I . Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13(5):459-65. DOI: 10.1016/S1470-2045(12)70090-6. View

14.

Davis F, Dolecek T, McCarthy B, Villano J . Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012; 14(9):1171-7. PMC: 3424213. DOI: 10.1093/neuonc/nos152. View

15.

Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F . Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2012; 14(1):64-71. DOI: 10.1016/S1470-2045(12)70432-1. View

16.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-95. DOI: 10.1016/S1470-2045(14)70061-0. View

17.

Kocher M, Wittig A, Piroth M, Treuer H, Seegenschmiedt H, Ruge M . Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol. 2014; 190(6):521-32. DOI: 10.1007/s00066-014-0648-7. View

18.

Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M . Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015; 91(4):710-7. DOI: 10.1016/j.ijrobp.2014.10.024. View

19.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

20.

Giaj Levra N, Sicignano G, Fiorentino A, Fersino S, Ricchetti F, Mazzola R . Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. Radiol Med. 2015; 121(1):60-9. DOI: 10.1007/s11547-015-0563-8. View